Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China

• Main Authors: Na Zeng, Cailun Zou, Zhiying He, Hong Ma, Xiaojuan Ou, Hong You, Yuanyuan Kong, Jidong Jia
• Format: Article
• Language: English
• Published: Elsevier 2018-02-01
• Series: International Journal of Infectious Diseases
• Subjects: Hepatitis B; Hepatitis C; Randomized clinical trial; CONSORT guidelines; Reporting quality; Treatment
• Online Access: http://www.sciencedirect.com/science/article/pii/S120197121730293X

Background: The numbers of articles reporting randomized controlled trials (RCTs) on viral hepatitis in China have been increasing, but there have been few systematic studies evaluating the reporting quality of RCTs in this field. This study was performed to assess the reporting quality of RCTs on the treatment of hepatitis B and C in China from 1991 to 2015. Methods: Articles published between January 1991 and December 2015 were identified via the PubMed, MEDLINE, and Embase databases using the key words “randomized clinical trials”, “treatment”, “therapy”, “hepatitis B”, “HBV”, “hepatitis C”, “HCV”, “China”, and “Chinese”. The reporting quality was assessed against the Consolidated Standards of Reporting Trials (CONSORT) checklist. Results: In total, 211 RCTs on the treatment of hepatitis B or C were included. The number of articles focusing on these RCTs increased rapidly over time, while the reporting quality improved steadily over time. Overall, compliance with the key components of the CONSORT checklist was low, with only 8.5%, 3.8%, and 11.4% of the articles fulfilling the reporting requirements of randomization, allocation concealment, and blinding, respectively. Conclusions: Both the number and the quality of RCT articles were found to have increased steadily over the last two decades. However, compliance with the key components of the CONSORT checklist still needs improvement. It is hoped that the results of this study will lead to improvements in the reporting quality of clinical trials on hepatitis B and C in China.